Fish oil is one of the oldest supplements known to man, and whether or not it’s effective has been a heated topic of discussions for health experts and companies like Prorganiq, with many looking for empirical evidence.
The latest to pour fuel into the fire is a new study that links the regular use of fish oil supplements to a lower risk of cardiovascular issues, like strokes and heart attacks, and premature death.
The study was conducted by a team from the Tufts University’s Cardiovascular Nutrition Laboratory. The Lab’s Director, Senior Scientist and Professor of Nutrition Science and Policy, Alice Lichtenstein states that, with regards to fish oil and CVD, the data has been positive for the most part, with some variance depending on the study; hence the differences in opinions between companies like Prorganiq and others. Prof. Lichtenstein was not involved in the study.
She stresses, however, that fish oil tablets is not a magical cure-all, and that the study wasn’t able to get solid data on the dosage required to get a meaningful effect.
The research was published early March in the BMJ Medical Journal, with a sample size of nearly half a million Brits, between the ages of 40 and 69 years, enrolled in the UK Biobank study. According to the research, about 1/3rd of the 427,678 adults in the databank stated that they regularly took fish oil supplements at the start of the study.
The study monitored its participants over a nine-year period with the aid of hospital and death records, and noted that fish oil supplements were associated with a 13% decrease in the risk of death, 16% decreased chance of dying from a cardiovascular disease, and a 7% decrease in the odds of a cardiovascular disease event happening like stroke or heart attack.
However, the authors noted that the data was independent of external factors like age, sex, diet, lifestyle habits, diet, medication, and other supplements. They attempted to control for these factors in order to determine the data, and carefully concluded that fish oil is associated with lower risks for CVD, CVD mortality, and all mortality events.